SCHEMBL14221256

SCHEMBL14221256

Cc1c[nH]c2ncncc2c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA5 O75582 1/20 0.41
MET P08581 1/20 0.36
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
LATS1 O95835 1/20 0.34
BAZ2A Q9UIF9 1/20 0.33
NTRK1 P04629 2/20 0.33
ROCK2 O75116 3/20 0.32
ROCK1 Q13464 1/20 0.32
CDC42BPB Q9Y5S2 1/20 0.32
LIMK1 P53667 2/20 0.32
AXL P30530 1/20 0.32
PRKCI P41743 1/20 0.32
TBK1 Q9UHD2 1/20 0.31
PIM1 P11309 1/20 0.31
PIM3 Q86V86 1/20 0.31
PIM2 Q9P1W9 1/20 0.31
AURKA O14965 1/20 0.31
TTK P33981 1/20 0.31
AURKB Q96GD4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29598321 0.85 RPS6KA5 (0.45) RPS6KA5METPRMT5WDR77LATS1
SCHEMBL2619224 0.85 RPS6KA5 (0.45) RPS6KA5METPRMT5WDR77LATS1
SCHEMBL6783900 0.75 CSNK2A1 (0.42) RPS6KA5NTRK1PIM3
SCHEMBL1797434 0.73 RPS6KA5 (0.42) RPS6KA5PRMT5WDR77LATS1BAZ2A
SCHEMBL13684670 0.71 ADORA2A (0.46)
SCHEMBL10044576 0.71 AXL (0.53) METAXLPIM1AURKA
SCHEMBL1093381 0.70 RPS6KA5 (0.43) RPS6KA5LATS1NTRK1ROCK2ROCK1
SCHEMBL13627414 0.70 HASPIN (0.46) RPS6KA5METNTRK1AXLTBK1
SCHEMBL1093217 0.70 RPS6KA5 (0.40) RPS6KA5METLATS1NTRK1TBK1
SCHEMBL23571474 0.69 RPS6KA5 (0.45) RPS6KA5LATS1NTRK1TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11225480-B2 Malic enzyme inhibitors SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-01-18 US disclosed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 US disclosed
US-20170313683-A1 BTK INHIBITOR HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2017-11-02 US disclosed
EP-1309565-B1 HETEROCYCLIC MUTILIN ESTERS AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115038-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 RPS6KA5 2091/4885MET 641/4885PRMT5 847/4885
US-11225480-B2 Malic enzyme inhibitors ME1, RNASE1, ME2 RPS6KA5 1380/4885MET 679/4885PRMT5 567/4885
US-20170313683-A1 BTK INHIBITOR BTK, SYK, LYN RPS6KA5 797/4885MET 2622/4885PRMT5 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.